Fatal trial incidents in China cast doubt on rapid review process

Three deaths in investigator-initiated trials in China have triggered concerns about the country's reputation for fast, low-cost clinical testing. These IITs permit experimental cell and gene therapies to be studied with less regulatory oversight. The incidents are prompting questions about whether speed and cost advantages come at the expense of patient safety.